Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418522 · ClinicalTrials.gov registry record · Phase 4
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 413
- Enrollment target
NCT00418522 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 413 participants.
The verdict
NCT00418522, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 413 participants
- Enrollment target
Study Summary
This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.
Interventions
- DRUG Insulin glargine
- DRUG Inhaled Insulin (Exubera)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418522
The ClinicalTrials.gov registry entry for NCT00418522 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine is the first listed.
NCT00418522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418522 about?
NCT00418522 is a clinical study titled "This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus". This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.
What is the current status of trial NCT00418522?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 413 participants. The study started on 2007-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00418522?
The interventions under investigation include: Insulin glargine (DRUG), Inhaled Insulin (Exubera) (DRUG).
Who is sponsoring clinical trial NCT00418522?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.